UBS has revised its target price for H Lundbeck A/S to DKK 45, down from DKK 49, while keeping a neutral stance on the stock.
Lundbeck is a Danish pharmaceutical company that specializes in the research, development, manufacturing, and marketing of products aimed at treating various brain disorders. Their product lineup includes Cipralex for depression and anxiety, Ebixa for Alzheimer's, Azilect for Parkinson's, Xenazine for Huntington's, and Sabril for epilepsy.
Lundbeck operates through several subsidiaries, including Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia, and Lundbeck LLC, which strengthens its presence in the global pharmaceutical market.